Asset Management One Co. Ltd. Has $61,000 Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Asset Management One Co. Ltd. grew its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 60.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,039 shares of the company’s stock after buying an additional 771 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Fulgent Genetics were worth $61,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in FLGT. Covington Capital Management boosted its holdings in shares of Fulgent Genetics by 133.3% in the third quarter. Covington Capital Management now owns 700 shares of the company’s stock valued at $27,000 after buying an additional 400 shares during the period. Geneos Wealth Management Inc. lifted its position in shares of Fulgent Genetics by 416.8% in the first quarter. Geneos Wealth Management Inc. now owns 491 shares of the company’s stock worth $30,000 after purchasing an additional 396 shares in the last quarter. Covestor Ltd lifted its position in shares of Fulgent Genetics by 48.0% in the third quarter. Covestor Ltd now owns 1,508 shares of the company’s stock worth $40,000 after purchasing an additional 489 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Fulgent Genetics in the fourth quarter worth $46,000. Finally, FMR LLC lifted its position in shares of Fulgent Genetics by 79.4% in the first quarter. FMR LLC now owns 1,864 shares of the company’s stock worth $58,000 after purchasing an additional 825 shares in the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Stock Down 1.4 %

Shares of FLGT stock opened at $20.78 on Monday. The company’s fifty day simple moving average is $23.14 and its 200-day simple moving average is $25.55. Fulgent Genetics, Inc. has a 12 month low of $20.62 and a 12 month high of $44.09. The firm has a market cap of $621.34 million, a PE ratio of -3.68 and a beta of 1.43.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.61. Fulgent Genetics had a negative net margin of 58.03% and a negative return on equity of 3.04%. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $67.14 million. On average, equities analysts predict that Fulgent Genetics, Inc. will post -2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Piper Sandler cut their price objective on shares of Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 6th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.